CROSS-FILE AUDIT
Compare the evidence, not the category
A shared grid for four unlike compounds: mechanism, model, endpoint and claim boundary.
Begin with the claim
These four compounds are grouped by the way people discuss them, not because they share one mechanism or one level of proof. Semaglutide is an incretin medicine with large outcomes trials. NAD+ is an endogenous coenzyme, usually studied through oral precursors. BPC-157 is an experimental peptide supported mainly by animal and cell work. PT-141 is the research name associated with an approved melanocortin medicine for a narrow clinical population.
A fair comparison starts by naming the claim. For weight and cardiovascular outcomes, semaglutide has direct human evidence [3][4]. For raising circulating NAD+, precursor trials answer the question; for longer life, they do not [8][12]. For BPC-157 repair, preclinical findings show plausibility while human efficacy remains unresolved [14][16][17]. For bremelanotide, controlled trials support changes in desire and distress in the studied population [20]. “Which is best?” has no coherent answer until the endpoint, population and evidence standard are specified.
Evidence matrix
| Compound | Primary mechanism | Strongest composed evidence | Studied endpoint | Main unsupported extension |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonism across pancreatic, digestive and central appetite pathways | Large randomized human trials [2][3][4] | Weight change; cardiovascular and kidney events | General wellness claims detached from trial populations |
| NAD+ | Redox coenzyme and substrate for sirtuins, PARPs and CD38-family enzymes | Small human precursor trials plus current review [8][9][10][12] | Blood NAD+; walking measures; muscle insulin sensitivity | Longevity and broad disease prevention |
| BPC-157 | Proposed VEGFR2, nitric-oxide and cell-migration signaling | Animal and cell research; tiny human pilots [13][14][16][17] | Experimental vessel, ulcer and repair measures | Reliable human injury healing or general recovery |
| PT-141 | Central MC4R and MC3R agonism | Phase 3 trials, extension and label [20][21][22] | Sexual desire and related distress in a defined population | Performance claims or transfer to unstudied groups |
Mechanism is the opening argument
A mechanism shows that a claim is biologically possible. Semaglutide’s receptor activity offers a coherent account of glucose regulation, gastric slowing and appetite signaling; rodent mapping identifies specific central circuits [6]. NAD+ sits even deeper in core cell biology, connecting energy transfer with DNA repair and signaling enzymes [11]. BPC-157 activates a vessel-growth pathway in experimental systems [16]. Bremelanotide changes melanocortin signaling and task-linked brain activity [19].
None of those sentences alone tells how much a person benefits. Clinical confidence rises when the chain continues through a controlled comparison, a relevant endpoint, a suitable population and enough observation to detect harm. Mechanistic elegance can make a weak evidence base sound finished. This audit treats it as the beginning.
Clinical outcomes and surrogate measures
Semaglutide has the broadest set of direct outcomes in the corpus. STEP 1 measured weight change [4], SELECT measured major cardiovascular events [3], and FLOW measured a kidney-disease composite [2]. Those endpoints differ, but each is closer to a health result than a pathway marker.
NAD+ research shows the value and limitation of surrogates. Trials can demonstrate that NMN or NR changes blood NAD+ [9][12]. A separate trial found a muscle-insulin-sensitivity change without shifts in body composition or glycated hemoglobin [10]. The biomarker response is real; the extrapolation to longevity remains unsupported by human outcomes [8].
BPC-157 sits earlier in translation. Vessel density, ulcer area and signaling activation are meaningful experimental outcomes [16][17], while the clinical bridge is missing [14]. PT-141 is further along because its trials used patient-reported measures built for the condition under study [20], though debate about clinical meaning can remain even after statistical significance.
Safety maturity follows exposure maturity
Large programs reveal patterns that tiny studies cannot. Semaglutide’s record identifies common gastrointestinal effects, biliary concerns and context-specific retinopathy findings [5][7]. PT-141’s trials and label identify nausea, flushing, headache, pigment changes and transient blood-pressure elevation [21][22]. These profiles are imperfect, but they rest on structured observation.
For BPC-157, absence of reported harm in a two-person pilot is weak reassurance [13]. Rare events and long-term effects require far more exposure. NAD+ precursor studies offer short-term tolerability data [9][12], while different routes and products cannot simply borrow that reassurance.
Evidence maturity therefore changes both sides of a claim. It strengthens the estimate of benefit and makes the account of harm more complete. An early compound can look unusually clean because too few people have been observed.
The editorial verdict
Semaglutide supports the strongest and broadest clinical claims in this set, within its studied metabolic and risk populations. PT-141 supports a narrower clinical claim through controlled trials and an approved label. NAD+ precursor research supports biomarker movement and selected early functional signals, with no demonstrated general longevity outcome. BPC-157 supports mechanistic and preclinical interest, while dependable human efficacy remains an open question.
The ranking changes with the question, but the method does not: identify the intervention, model, comparator, endpoint, population and time horizon. Then stop the claim at the last link the evidence actually establishes.